+

WO2008121160A3 - Optimized antibodies that target cd5 - Google Patents

Optimized antibodies that target cd5 Download PDF

Info

Publication number
WO2008121160A3
WO2008121160A3 PCT/US2007/083247 US2007083247W WO2008121160A3 WO 2008121160 A3 WO2008121160 A3 WO 2008121160A3 US 2007083247 W US2007083247 W US 2007083247W WO 2008121160 A3 WO2008121160 A3 WO 2008121160A3
Authority
WO
WIPO (PCT)
Prior art keywords
target
antibodies
optimized antibodies
parent antibody
alters
Prior art date
Application number
PCT/US2007/083247
Other languages
French (fr)
Other versions
WO2008121160A2 (en
Inventor
Matthew J Bernett
John R Desjarlais
Sher Bahadur Karki
Eugene Alexander Zhukovsky
Erik Weiking Pong
Seung Yup Chu
Original Assignee
Xencor Inc
Matthew J Bernett
John R Desjarlais
Sher Bahadur Karki
Eugene Alexander Zhukovsky
Erik Weiking Pong
Seung Yup Chu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xencor Inc, Matthew J Bernett, John R Desjarlais, Sher Bahadur Karki, Eugene Alexander Zhukovsky, Erik Weiking Pong, Seung Yup Chu filed Critical Xencor Inc
Publication of WO2008121160A2 publication Critical patent/WO2008121160A2/en
Publication of WO2008121160A3 publication Critical patent/WO2008121160A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcgR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
PCT/US2007/083247 2006-11-21 2007-10-31 Optimized antibodies that target cd5 WO2008121160A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86679306P 2006-11-21 2006-11-21
US60/866,793 2006-11-21

Publications (2)

Publication Number Publication Date
WO2008121160A2 WO2008121160A2 (en) 2008-10-09
WO2008121160A3 true WO2008121160A3 (en) 2009-01-22

Family

ID=39808822

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/083247 WO2008121160A2 (en) 2006-11-21 2007-10-31 Optimized antibodies that target cd5

Country Status (1)

Country Link
WO (1) WO2008121160A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3056568B1 (en) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
MX369784B (en) 2007-09-26 2019-11-21 Chugai Pharmaceutical Co Ltd Method of modifying isoelectric point of antibody via amino acid substitution in cdr.
SG10201608379YA (en) 2008-04-11 2016-11-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CN102753579A (en) 2009-05-01 2012-10-24 国立大学法人东京大学 Anti-cadherin antibody
WO2011089211A1 (en) * 2010-01-22 2011-07-28 Synimmune Gmbh Anti-cd133 antibodies and methods of using the same
CN103080130B (en) 2010-05-27 2016-08-17 默沙东公司 Preparation has the method for the antibody improving characteristic
CN108715614A (en) 2010-11-30 2018-10-30 中外制药株式会社 The antigen binding molecules combined are repeated with polymolecular antigen
WO2014030750A1 (en) 2012-08-24 2014-02-27 中外製薬株式会社 MOUSE FcγRII-SPECIFIC Fc ANTIBODY
JP6501521B2 (en) 2012-08-24 2019-04-17 中外製薬株式会社 FcγRIIb-specific Fc region variant
CN113621057A (en) 2013-04-02 2021-11-09 中外制药株式会社 Fc region variants
IL278014B2 (en) 2014-12-19 2023-10-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
TWI844732B (en) 2015-02-05 2024-06-11 日商中外製藥股份有限公司 Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN116251182A (en) 2016-08-05 2023-06-13 中外制药株式会社 Compositions for preventing or treating IL-8 related diseases
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP7458975B2 (en) * 2017-11-29 2024-04-01 マジェンタ セラピューティクス インコーポレイテッド Compositions and methods for depletion of CD5+ cells
IL277375B1 (en) 2018-03-15 2025-04-01 Chugai Pharmaceutical Co Ltd Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
US11555071B2 (en) 2018-06-03 2023-01-17 Lamkap Bio Beta Ltd. Bispecific antibodies against CEACAM5 and CD47
CN112739340B (en) * 2018-07-23 2025-05-13 海德堡医药研究有限责任公司 Use of anti-CD5 antibody drug conjugates (ADCs) in allogeneic cell therapy
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
EP3915641A1 (en) * 2020-05-27 2021-12-01 International-Drug-Development-Biotech Anti-cd5 antibodies and methods of use thereof
WO2022040608A1 (en) * 2020-08-21 2022-02-24 City Of Hope Anti-cd5 antibody compositions and uses thereof
EP4211245A1 (en) 2020-09-14 2023-07-19 Vor Biopharma Inc. Compositions and methods for cd5 modification
CN116801905A (en) * 2020-12-17 2023-09-22 先声再明医药有限公司 CD5 antibodies and their applications
MX2023007220A (en) 2020-12-18 2023-08-25 Lamkap Bio Beta Ltd Bispecific antibodies against ceacam5 and cd47.
WO2022152185A1 (en) * 2021-01-12 2022-07-21 南京驯鹿医疗技术有限公司 Cd5-targeting fully humanized antibody
CN113105547B (en) * 2021-05-18 2022-04-08 福州迈新生物技术开发有限公司 anti-CD 5 protein monoclonal antibody and cell strain, preparation method and application thereof
US12077597B2 (en) 2021-11-24 2024-09-03 International-Drug-Development-Biotech Anti-CD5 antibodies and methods of use thereof
AU2023291779A1 (en) 2022-06-16 2024-10-17 Lamkap Bio Beta Ltd Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008883A1 (en) * 2003-12-04 2006-01-12 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
WO2006105338A2 (en) * 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008883A1 (en) * 2003-12-04 2006-01-12 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
WO2006105338A2 (en) * 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANTIN J H ET AL: "Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies.", BLOOD 15 OCT 1991, vol. 78, no. 8, 15 October 1991 (1991-10-15), pages 2139 - 2149, XP002505318, ISSN: 0006-4971 *
CIOCA D P ET AL: "Apoptosis induction by hypercross-linking of the surface antigen CD5 with anti-CD5 monoclonal antibodies in B cell chronic lymphocytic leukemia.", LEUKEMIA : OFFICIAL JOURNAL OF THE LEUKEMIA SOCIETY OF AMERICA, LEUKEMIA RESEARCH FUND, U.K MAR 2002, vol. 16, no. 3, March 2002 (2002-03-01), pages 335 - 343, XP002505317, ISSN: 0887-6924 *
PERS J O ET AL: "CD5-induced apoptosis of B cells in some patients with chronic lymphocytic leukemia.", LEUKEMIA : OFFICIAL JOURNAL OF THE LEUKEMIA SOCIETY OF AMERICA, LEUKEMIA RESEARCH FUND, U.K JAN 2002, vol. 16, no. 1, January 2002 (2002-01-01), pages 44 - 52, XP002505316, ISSN: 0887-6924 *
STUDNICKA G M ET AL: "HUMAN-ENGINEERED MONOCLONAL ANTIBODIES RETAIN FULL SPECIFIC BINDINGACTIVITY BY PRESERVING NON-CDR COMPLEMENTARITY-MODULATING RESIDUES", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 7, no. 6, 1 June 1994 (1994-06-01), pages 805 - 814, XP000447301, ISSN: 0269-2139 *

Also Published As

Publication number Publication date
WO2008121160A2 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
WO2008121160A3 (en) Optimized antibodies that target cd5
WO2008022152A3 (en) Optimized antibodies that target cd19
WO2008091798A3 (en) Optimized ca9 antibodies and methods of using the same
WO2008091954A3 (en) Optimized cd40 antibodies and methods of using the same
WO2008098115A3 (en) Optimized igf-1r antibodies and methods of using the same
WO2007044616A3 (en) Optimized anti-cd30 antibodies
WO2009026117A3 (en) Novel compounds
WO2007024846A3 (en) Anit-il-23 antibiodies
WO2008036688A3 (en) Optimized antibodies that target hm1.24
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
WO2008048519A3 (en) Antibodies that bind cxcr7 epitopes
WO2008070344A3 (en) Compositions and methods for binding sphingosine-1-phosphate
WO2004072266A3 (en) Antibody affinity engineering by serial epitope-guided complementarity replacement
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
WO2006130374A3 (en) Tweak binding antibodies
WO2009070243A3 (en) Wise binding antibodies and epitopes
WO2008060705A3 (en) Anti-dll4 antibodies and methods using same
WO2009071696A3 (en) Humanized antibody molecules specific for il-31
WO2007008583A3 (en) Improved protein expression comparison assay results and applications
WO2007130697A8 (en) Anti-ephb4 antibodies and methods using same
WO2008094538A3 (en) Regulatory t cell epitopes, compositions and uses thereof
WO2008003116A3 (en) Method for engineering immunoglobulins
WO2006135527A3 (en) Methods for the selection of aptamers
WO2008143697A3 (en) Antibody with protein a selectivity
WO2008140570A3 (en) Antibody with protein a selectivity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07873582

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07873582

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载